Lumenis Be. Ltd. is introducing FoLix, the first fractional laser to treat hair loss.
Recently cleared by the U.S. Food and Drug Administration, FoLix is a non-ablative fractional laser device to improve the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss.
Pre-clinical and clinical studies showed a positive impact on hair growth, with noticeable improvements in scalp hair appearance and an increase in hair count,
“Fractional lasers have been shown to have remarkable effects on the skin and now, finally, Lumenis has been able to harness that power and bring an innovative solution for hair stimulation,” says Marc Avram, MD, a hair transplant specialist and Clinical Professor of Dermatology at Weill Cornell Medical College (WCMC) in New York City.
“With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers,” adds Neil Sadick, MD, a dermatologist and researcher, and Clinical Professor of Dermatology at WCMC. “FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.”
Several treatments are needed for optimal results. FoLix treatment could cause redness, swelling, scarring, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, active infection, fungal or bacterial diseases.
